Premium
Comparison of melphalan with cyclophosphamide, methotrexate, and 5‐fluorouracil in patients with ovarian cancer
Author(s) -
Brodovsky Harvey S.,
Bauer Madeline,
Horton John,
Elson Paul J.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840215)53:4<844::aid-cncr2820530405>3.0.co;2-n
Subject(s) - medicine , melphalan , cyclophosphamide , methotrexate , fluorouracil , gastroenterology , chemotherapy , stage (stratigraphy) , progressive disease , surgery , paleontology , biology
Melphalan (L‐PAM) was compared to (C) cyclophosphamide, (M) methotrexate, and (F) 5‐fluorouracil (CMF) in 413 patients with advanced ovarian carcinoma. L‐PAM was given 3.5 mg/m 2 twice daily for 5 days every 5 weeks. CMF doses were: C, 400 mg/m 2 ; M, 15 mg/m 2 ; and F, 400 mg/m 2 IV on days 1 and 8 every 28 days. Three hundred seventy‐five patients have been analyzed (L‐PAM, 190; CMF, 185). One hundred fifty‐three patients (41%) had measurable disease, 109 (29%) had evaluable disease, and 113 (30%) had nonmeasurable, nonevaluable disease. Response rates for patients with measurable and evaluable disease combined were similar: L‐PAM, 32/130 (24%) (15% complete response); CMF, 47/132 (35%) (18% complete response). Patients with Stage IV measurable disease had a greater response rate to CMF, 22/52 (42%) versus L‐PAM, 6/39 (15%). Survival and time to treatment failure were similar for both treatment regimens. Survival was improved in responders. Medians are: complete response, 28.1 months; partial response, 12.3 months; and no response, 6.7 months. Disease stage, performance status and age were identified as important prognostic variables for both survival and time to treatment failure.